Xi Wang
    Title Professor, Director of Breast Oncology Department

    Clinical Studies of Breast Oncology.

    Dr. Wang is experienced with breast cancer surgery (radical surgery, and comprehensive treatment of mammary gland reconstruction), chemotherapy, endocrine treatment and targeted therapy

    1984 – 1996 Physician, People’ Hospital of Fuzhou, Jiangxi Province

    2004 - Present Physician, Department of Breast Oncology, Sun Yat-Sen University Cancer Center

    Research Interest(s)

    1979 - 1984 MD, Jiangxi Medical College

    1996 - 2001 MM & PhD, Sun Yat-Sen University, School of Medicine

    2001 - 2004 Post- Doctor, Sun Yat-Sen University


    Last updated on: April, 2014


    Xiaoming Xie
    Title Professor

    Dr. Xiaoming Xie is Surgeon and Chairman of the Department of Breast Oncology and Director of the Laboratory of Cancer Biotechnology in the State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center. Dr. Xie obtained his M.D. in 1986 and his Ph.D. in 1994 from Central South University. He later got postdoctoral training at the University of Navarra in Spain and University of Florida in USA. Dr.Xie worked as Research Associate in the Department of Immunology, Baylor College of Medicine, Houston, Texas, USA, during 1999 to 2003.

    Since 2003, Dr. Xie became Research Scientist and Translational Group Leader at the University of Texas MD Anderson Cancer Center, Texas. Dr. Xie has gained multiple awards including the AstraZeneca Award, USA (2005), the Best Prize of the 10th Annual Oncology Research Seminar. USA (2001), the Travel Grant of the 6th Conference on retroviruses and Opportunistic Infections, USA (1999) and the Best Oral Presentation Award of Terapia genica del hepatocarcinoma mediate la transferencia del gen la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain (1998) as well as Dr. Sir Q.W. Lee fellowship. USA (1997).

    In 2008, he founded the Department of Breast Oncology in Sun Yat-sen University Cancer Center, Guangzhou, where he serves as the Chairman, Surgeon and Professor. His major research interests are targeted biotherapy for cancer, novel animal models for in vivo imaging, nanoparticle biotechnology, mechanism of development, metastasis and recurrence of breast cancer and basic and clinical research and clinical trial of breast cancer and clinical services (surgery and medical oncology).

    Dr. Xiaoming Xie has published more than 60 peer-reviewed articles (including Nature Cell Biology, Cancer Cell, Cancer Research) with 11 patents and 3 ongoing clinical trials at MD Anderson Cancer Center. He is specialized in multidisciplinary care of breast cancer and translational research and clinical trials, as well as the primary investigator and co-investigator of more than 20 ongoing research projects and clinical trails supported by various grants.

    Phone Tel: 020-61639540(O), 13826109540 (Cell)Fax: 020-38320368
    Research Interest(s)

    1. Molecular biology of breast cancer/stem cells

    2. Living imaging animal models of breast cancer /stem cells

    3. Early diagnosis and biomarkers of breast cancer4. Nanoparticle-based targeted therapy


    1981 - 1986 MD, Central South University Xiangya Medical College ( Faculty of Medicine, Hunan Medical University)

    1990 – 1994 Ph.D., Molecular Virology and Oncology, Department of Internal medicine, Central South University Xiangya Medical College (Hunan Medical University)


    Selected publications

    1. Xie, X., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925).

    2. Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873)

    3. Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung () and X Xie(). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226)

    Last updated on: 2012

    Wang Jin
    Title Associate Professor

    Dr. Jin Wang is currently an Associate Professor in the Department of Breast Oncology at SYSUCC. She specializes in breast oncology and is a renowned young oncological surgeon in China. Dr. Jin Wang graduated from Peking Union Medical College and obtained her M.D. degree in 2012, and then worked as a surgeon at SYSUCC. From 2019 to 2020, Dr. Jin Wang was a Postdoctoral Fellow in the Department of Surgical Oncology at Massachusetts General Hospital, Harvard University. Dr. Jin Wang serves as a Youth Committee member in multiple academic associations (e.g. the Chinese Society of Clinical Oncology, Guangdong Medical Association). She is also passionate about medical teaching and was awarded one of “2018's Outstanding Teachers of Surgical Residency Training”. Dr. Jin Wang was also awarded one of the “Most Promising Young Oncologists" in 2017 (by CSCO). 

    Phone +86-20-8734-3806
    Research Interest(s)
    Clinical Research: 1) Diagnosis and Treatment of early and advanced breast cancer; 2) Oncoplastic Surgery of breast cancer

    Basic and Translational Research: 1) Mechanism of the growth and metastasis of triple-negative breast cancer; 2) Targeted therapy of triple-negative breast cancer; 3) Nanoparticle biotechnology; 4) Breast cancer susceptibility genes

    Postdoctoral Fellow, Department of Surgical Oncology, Massachusetts General Hospital, Harvard University

    M.D. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    M.M. 7-Year-Program Clinical Medicine, Harbin Medical University


    Selected publications
    1. Wang J#*, Tang H#, Li X, Song C, Xiong Z, Wang X, Xie X, Tang J*. Is surgical axillary staging necessary in women with T1 breast cancer who are treated with breast-conserving therapy? Cancer Commun. 2019;39(1):25.

    2. Tang H#, Huang X#, Wang J#, Yang L, Kong Y, Gao G, Zhang L, Chen ZS, Xie X*. circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer. Mol Cancer. 2019;18(1):23.

    3. Wang J#*, Song C#, Tang H#, Zhang C, Tang J, Li X, Chen B, Xie X*. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017;19(1):72.

    4. Chen B#, Wang J#, Dai D#, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X*. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 2017;36(1):65.

    5. Wang J#*, Zhang C#, Tang H#, Tang H, Tang J, Song C, Xie X*. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:255-269.

    6. Song C#, Zhang L#, Wang J#, Huang Z, Li X, Wu M, Li S, Tang H, Xie X*. High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Sci Rep. 2016; 6: 24502.

    7. Li X#, Tang H#, Wang J#, Xie X, Liu P, Kong Y, Ye F, Shuang Z, Xie Z, Xie X*. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2016;32:1-6.

    8. Wang J*, Zhang X, He J, Yang M, Tang J, Li X, Tang H, Xie X. Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 2014;31(9):172.

    9. Wang J*, Xiaoming Xie*, Xi Wang, Tang J, Pan Q, Zhang Y, Di M. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol. 2013;22:247-255.

    10. Wang J#*, Kang WM#, Yu JC, Liu YQ, Meng QB, Cao ZJ. Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NF-κB signaling pathway. Cancer Biol Ther. 2013;14:3:262-270.

    11. Wang J*, Yu JC*, Kang WM, Liu YQ, Meng QB, Cao ZJ. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer. Ann Surg Oncol. 2012;19(5):1529-1534.

    12. Wang J*, Yu JC*, Kang WM, Ma ZQ. Superiority of a fish oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: a randomized clinical trial. Nutrition. 2012;28(6):623-629.

    13. Wang J*, Yu JC*, Kang WM, Ma ZQ. Treatment strategy for early gastric cancer. Surg Oncol. 2012;21(2):119-123.

    14. Wang J*, Yu JC*, Kang WM, Ma ZQ. Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. J Surg Oncol. 2012;105(4):400-404.

    Updated April 2021

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.